Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial

Palacios, Santiago; Wildt, L.; Parke, Susanne; Machlitt, A.; Römer, Thomas; Bitzer, Johannes

doi:10.1016/j.ejogrb.2009.11.001

Cited by 79 publications

(70 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of note, is the weight loss seen in this study with E2V/DNG at cycle 6, with a similar magnitude to the weight loss seen with E4/DRSP. This is in contrast to previous studies with E2V/DNG, where weight gain was reported as one of the most common adverse events and reason for treatment discontinuation [25].…”

Section: Findings and Interpretationcontrasting

confidence: 53%

Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control

Apter

Zimmerman

Beekman

et al. 2017

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

Section: Findings and Interpretationcontrasting

confidence: 53%

Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control

Apter

Zimmerman

Beekman

et al. 2017

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

“…Нежелательные явле-ния, связанные с E2В/ДНГ (с учетом как минимум всех возможных связанных с проводимой терапией нежела-тельных явлений), наблюдались реже -у 19,8% женщин. Среди них отмечены изменения цикла (1,7%), угревая сыпь (1,0%), прибавка веса (0,9%) [18]. В другом исследо-вании [16] сообщается о частоте внеплановых кровотече-ний, которая была аналогична в группах для ДНГ и ЛНГ (14 и 12% соответственно), что было характерно для первого месяца лечения.…”

Section: ключевые словаunclassified

“…То есть частота отказов от дальней-шего приема составила около 20% [18]. В отношении E2/НМГА, по данным европейских исследований, частота отказов составляет менее 30%, а американских -дости-гает почти 40% [14,17].…”

Section: ключевые словаunclassified

How to reduce the number of side effects produced by COCs and improve adherence: simple tips for practitioners

Dikke

2016

Medicinskij sovet

View full text Add to dashboard Cite

The frequency and severity of side effects induced by the use of combined oral contraceptives (COCs) are the most common causes of withdrawal (64.4%). Better adherence can be achieved through adequate counselling on the choice of contraception and use of extended-regimen low-dose COCs with estrogen component and natural hormones containing novel selective progestins (dienogest, drospirenone) with minimum side effects. The choice of vitamin and mineral supplements based on the relevant micronutrient disbalance in women using COCs and "quick starting" could also contribute to compliance with the chosen method of oral contraception.

show abstract

“…Estradiol valerate 2 mg is bioequivalent to 1.5 mg micronized estradiol. 29,30 The estradiol is further metabolized into estrone and estrone sulfate following the same hepatic metabolic pathways observed during metabolism of ovarian-produced estradiol.…”

Section: Pharmacodynamics Componentsmentioning

confidence: 99%

New developments in oral contraception: clinical utility of estradiol valerate/dienogest (Natazia®) for contraception and for treatment of heavy menstrual bleeding: patient considerations

Nelson¹

2012

OAJC

View full text Add to dashboard Cite

Natazia ® is a new oral contraceptive with estradiol valerate and dienogest in a unique multiphasic formulation that includes a shortened hormone-free interval. This new formulation has been approved for both contraception and also as a treatment for heavy menstrual bleeding in women who desire to use oral contraceptives as their method of birth control. It is marketed in the US as Natazia ® and elsewhere as Qlaira ® . This article will review the properties of each of the major new features of this pill: estradiol used in place of ethinyl estradiol, dienogest as the progestin, and the unique dosing pattern of this product. It will also summarize the results of the pivotal clinical trials of contraceptive effectiveness, bleeding patterns, safety and tolerability. The lessons learned from the clinical trials about the effectiveness of this formulation in the treatment of excessive menstrual bleeding will be summarized. Also, results of trials comparing this new pill to other popular formulations for "menstrually-related" symptoms and for potential female sexual dysfunction related to use of oral contraceptives will be presented. This review will suggest how all this information might be used to counsel women about how to use this pill most successfully.

show abstract

Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial

Cited by 79 publications

References 22 publications

Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control

Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control

How to reduce the number of side effects produced by COCs and improve adherence: simple tips for practitioners

New developments in oral contraception: clinical utility of estradiol valerate/dienogest (Natazia®) for contraception and for treatment of heavy menstrual bleeding: patient considerations

Contact Info

Product

Resources

About

Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial

Cited by 79 publications

References 22 publications

Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control

Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control

How to reduce the number of side effects produced by COCs and improve adherence: simple tips for practitioners

New developments in oral contraception: clinical utility of estradiol valerate/dienogest (Natazia&reg;) for contraception and for treatment of heavy menstrual bleeding: patient considerations

Contact Info

Product

Resources

About

New developments in oral contraception: clinical utility of estradiol valerate/dienogest (Natazia®) for contraception and for treatment of heavy menstrual bleeding: patient considerations